Gencurix Inc. Logo

Gencurix Inc.

Develops and commercializes diagnostic solutions for precision medicine in oncology.

229000 | KO

Overview

Corporate Details

ISIN(s):
KR7229000005
LEI:
Country:
South Korea
Address:
서울특별시 구로구 디지털로 243 지하이시티 15층, 구로구

Description

Gencurix Inc. is a molecular diagnostics company that develops and commercializes diagnostic solutions for precision medicine. The company's portfolio focuses primarily on oncology, offering prognostic, companion, and early detection tests. Key products include GenesWell BCT, a multigene prognostic test for early-stage breast cancer, and the GenesWell ddEGFR Mutation Test, a ddPCR-based companion diagnostic. Gencurix also utilizes its Droplex liquid biopsy platform for early cancer detection and develops diagnostic tests for infectious diseases. The company's core technologies include digital droplet PCR (ddPCR), real-time PCR, and liquid biopsy for analyzing circulating tumor cells (CTCs) and cell-free DNA (cfDNA).

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2023-04-20 00:00
전환가액의조정(제5회차)
Korean 12.3 KB
2023-04-19 00:00
유상증자또는주식관련사채등의청약결과(자율공시)(실권주 일반공모분)
Korean 9.9 KB
2023-04-14 00:00
유상증자또는주식관련사채등의청약결과(자율공시)(구주주배정분)
Korean 9.1 KB
2023-04-10 00:00
유상증자최종발행가액확정
Korean 10.7 KB
2023-04-10 00:00
[기재정정]주요사항보고서(유상증자결정)
Korean 35.2 KB
2023-04-10 00:00
[발행조건확정]증권신고서(지분증권)
Korean 372.4 KB
2023-04-10 00:00
[기재정정]투자설명서
Korean 2.7 MB
2023-04-04 00:00
주식등의대량보유상황보고서(약식)
Korean 63.0 KB
2023-04-04 00:00
주식등의대량보유상황보고서(일반)
Korean 98.8 KB
2023-04-04 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 21.3 KB
2023-04-04 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.6 KB
2023-04-04 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 21.4 KB
2023-04-03 00:00
주식등의대량보유상황보고서(약식)
Korean 59.3 KB
2023-03-31 00:00
정기주주총회결과
Korean 21.5 KB
2023-03-23 00:00
감사보고서제출
Korean 25.2 KB

Automate Your Workflow. Get a real-time feed of all Gencurix Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Gencurix Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Gencurix Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.